PRIME MEDICINE INC (PRME) Forecast, Price Target & Analyst Ratings

NASDAQ:PRME • US74168J1016

Current stock price

3.35 USD
-0.29 (-7.97%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PRIME MEDICINE INC (PRME).

Forecast Snapshot

Consensus Price Target

Price Target
$6.59
+ 96.82% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.25
Revenue Estimate
677.79K
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$6.59
Upside
+ 96.82%
From current price of $3.35 to mean target of $6.59, Based on 17 analyst forecasts
Low
$4.29
Median
$6.12
High
$9.45

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

17 Wall Street analysts provided a forecast for the next 12 months for PRME. The average price target is 6.59 USD. This implies a price increase of 96.82% is expected in the next year compared to the current price of 3.35.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

PRME Current Analyst RatingPRME Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

PRME Historical Analyst RatingsPRME Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
PRME was analyzed by 17 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about PRME.
In the previous month the buy percentage consensus was at a similar level.
PRME was analyzed by 17 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-12OppenheimerInitiate Outperform
2025-12-23LifeSci CapitalInitiate Outperform
2025-11-11CitigroupMaintains Neutral -> Neutral
2025-11-10Chardan CapitalMaintains Buy -> Buy
2025-08-08Chardan CapitalMaintains Buy -> Buy
2025-05-27CitigroupDowngrade Buy -> Neutral
2025-05-20JMP SecuritiesMaintains Market Outperform -> Market Outperform
2025-05-20JP MorganDowngrade Overweight -> Neutral
2025-05-20HC Wainwright & Co.Downgrade Buy -> Neutral
2025-05-19Chardan CapitalMaintains Buy -> Buy
2025-03-20Chardan CapitalMaintains Buy -> Buy
2025-03-19HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-04Citizens Capital MarketsReiterate Market Outperform -> Market Outperform
2025-03-03Chardan CapitalMaintains Buy -> Buy
2025-03-03HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-10JMP SecuritiesInitiate Market Outperform
2024-12-03GuggenheimReiterate Buy -> Buy
2024-11-13Chardan CapitalMaintains Buy -> Buy
2024-11-13HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-25HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-02HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-09HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-20HC Wainwright & Co.Initiate Buy
2024-05-16CitigroupUpgrade Neutral -> Buy
2024-05-13JP MorganMaintains Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.25
Revenue Estimate
677.79K
Revenue Q2Q
-53.38%
EPS Q2Q
36.28%
Number of Analysts
13

Next Earnings Revisions

Revenue (1 Month)
32.90%
Revenue (3 Months)
66.13%
EPS (1 Month)
-3.90%
EPS (3 Months)
-3.90%

Next Earnings Summary

PRME is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.25 USD and the consensus revenue estimate is 677.79K USD.
The next earnings revenue estimate has been revised upward by 66.13% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
PRME revenue by date.PRME revenue by date.
2.983M4.632M
55.28%		4.413M
-4.73%		4.413M1.575M
-64.31%		7.009M
345.02%		20.754M
196.11%		111.87M
439.03%		520.47M
365.25%		1.009B
93.86%
EBITDA
YoY % growth
PRME ebitda by date.PRME ebitda by date.
-200.139M
-75.07%		-196.339M
1.90%		-201.029M
-2.39%		-163.331M
18.75%		-176.637M
-8.15%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
PRME ebit by date.PRME ebit by date.
-204.792M
-75.73%		-202.467M
1.14%		-208.35M
-2.91%		-168.91M
18.93%		-187.322M
-10.90%		-196.094M
-4.68%		-216M
-10.15%		-201.181M
6.86%		-138.585M
31.11%		199.31M
243.82%		524.59M
163.20%
Operating Margin
PRME operating margin by date.PRME operating margin by date.
N/A-6,787.36%-4,498.06%-3,827.56%-4,244.79%-12,450.44%-3,081.76%-969.36%-123.88%38.29%51.99%
EPS
YoY % growth
PRME eps by date.PRME eps by date.
-2.18
26.93%		-1.65
24.31%		-1.39
15.76%		-0.96
31.23%		-0.89
6.48%		-0.87
3.02%		-0.78
10.00%		-0.70
10.78%		-0.34
51.65%		0.77
327.27%		2.24
192.67%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28
EPS
Q2Q % growth		-0.25
36.28%		-0.24
40.82%		-0.25
22.86%		-0.27
-2.66%		-0.29
-14.85%		-0.31
-28.64%		-0.32
-27.69%		-0.33
-22.29%		-0.35
-20.21%		-0.38
-21.57%		-0.38
-21.68%
Revenue
Q2Q % growth		677.79K
-53.38%		7.293M
554.08%		7.293M
495.35%
-100.00%		N/AN/AN/AN/AN/AN/AN/A
EBITDA
Q2Q % growth		-49.321M
2.70%		-38.302M
23.11%		-39.148M
19.33%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-45.874M
12.44%		-42.261M
20.83%		-43.903M
18.66%		-49.062M
-0.93%		N/AN/AN/AN/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

PRME Yearly Revenue VS EstimatesPRME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
PRME Yearly EPS VS EstimatesPRME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
11.23%
EPS Next 5 Year
8.44%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-35.37%
Revenue Next 5 Year
28.89%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

PRIME MEDICINE INC / PRME Forecast FAQ

What is the price target for PRME stock?

17 analysts have analysed PRME and the average price target is 6.59 USD. This implies a price increase of 96.82% is expected in the next year compared to the current price of 3.35.

When does PRIME MEDICINE INC (PRME) report earnings?

PRIME MEDICINE INC (PRME) will report earnings on 2026-05-06.

What are the consensus estimates for PRME stock next earnings?

The consensus EPS estimate for the next earnings of PRIME MEDICINE INC (PRME) is -0.25 USD and the consensus revenue estimate is 677.79K USD.

How do analysts rate PRIME MEDICINE INC (PRME)?

The consensus rating for PRIME MEDICINE INC (PRME) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.